Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Ascentage Pharma Group Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04942067CT.gov APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04984330CT.gov Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | — | Withdrawn | — | — | — |
NCT04270175CT.gov Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab | — | Active Not Recruiting | — | — | — |
NCT03959358CT.gov A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | — | Completed | — | — | — |
NCT02924272CT.gov Ixazomib Rollover Study | — | Completed | — | — | — |
NCT01864018CT.gov Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | — | Completed | — | — | — |
NCT01383759CT.gov Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyloidosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Ascentage Pharma Group Inc. | P3 | BB · 70 |
| Acoramidis | Bayer | P4 | BBB |
| Empagliflozin | Columbia University | P4 | BB |
| Tafamidis | Pfizer | P4 | BB |
| Cyclophosphamide | University of Alabama at Birmingham | P2 | BB |
| Lenalidomide | Ascentage Pharma Group Inc. | P3 | BB |
| Enavogliflozin | Seoul St. Mary's Hospital | P4 | BB |
| Evuzamitide | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | BB |
| Inotersen | Brigham and Women's Hospital | P3 | BB |
+26 more in the Amyloidosis cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in Amyloidosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-amyloidosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →